Stryker to Acquire Inari Medical

January 6, 2025—Stryker announced a definitive agreement to acquire Inari Medical, Inc. for approximately $4.9 billion. Inari was founded in 2011.

The press release noted that the acquisition brings Inari’s position in the peripheral vascular field and venous thromboembolism segment to Stryker.

Inari’s product portfolio is complementary to Stryker’s Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, stated Stryker.

“The acquisition of Inari expands Stryker’s portfolio to provide life-saving solutions to patients who suffer from peripheral vascular diseases,” commented Kevin Lobo, Chair and Chief Executive Officer, Stryker, in the press release. “These innovations elevate the standard of care for venous thromboembolism patients and will accelerate Stryker’s impact in endovascular procedures.”

Drew Hykes, Chief Executive Officer, Inari, added, “Inari has positively impacted the lives of hundreds of thousands of patients through the development of purpose-built tools that address unmet patient needs. With Stryker’s capabilities and global infrastructure, we will be even better positioned to accelerate the development of innovative new solutions and expand our footprint.”

The press release advised that the boards of directors of both Stryker and Inari have unanimously approved the transaction.

Under the terms of the definitive agreement, Stryker will commence a tender offer for all issued and outstanding shares of common stock of Inari for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.

The transaction is anticipated to close by the end of the first quarter 2025, subject to customary closing conditions, stated Stryker.